Latest Stock Market News

Why OpGen (OPGN) Shares Are Trading Higher Today – OpGen (NASDAQ:OPGN)


  • OpGen Inc OPGN announced topline data from its Unyvero urinary tract infections (UTI) clinical trial. 
  • OpGen’s Unyvero UTI Panel tests for a broad range of bacterial and fungal pathogens and antimicrobial resistance markers directly from urine specimens. 
  • The test aims at the quantitative detection of microorganisms.
  • The trial was designed to compare the performance of the Unyvero UTI Panel for detecting urinary tract infections (UTI) using clean-catch or catheter-related urine samples. 
  • The study met the primary endpoint and exhibited an overall weighted average sensitivity of 96.4% and an overall weighted average specificity of 97.4% when compared against each trial site’s standard of care microbiology results. 
  • Related: OpGen Stock Gains On FDA Approval, Interim Q3 Sales.
  • The trial included 1,858 prospective and archived samples and has run over 3,300 Unyvero cartridges, including controls and reproducibility tests performed at the different trial sites. 
  • Based on all the data generated and analyzed, OpGen will start preparing a De Novo request package for submission to the FDA in due course.
  • OpGen intends to present data at a future conference and submit it for a peer-reviewed publication.
  • Price Action: OPGN shares are up 146.30% at $0.30 on the last check Tuesday.



Read More: Why OpGen (OPGN) Shares Are Trading Higher Today – OpGen (NASDAQ:OPGN)

You might also like